Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia.
COVID-19
SARS-CoV-2
aplastic anemia
cytokine storm
tocilizumab
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
15
05
2020
accepted:
17
08
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
While cytokine storm develops in a minority of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, novel treatment approaches are desperately needed for those in whom it does. Tocilizumab, an interleukin-6 receptor antibody, has been utilized for the treatment of cytokine storm in a number of severe inflammatory conditions, including in patients with severe coronavirus disease 2019 (COVID-19). Here, we present the first published case utilizing this therapy in a patient with underlying immunodeficiency. Our patient with aplastic anemia developed cytokine storm due to COVID-19 manifested by fever, severe hypoxia, pulmonary infiltrates, and elevated inflammatory markers. Following treatment with tocilizumab, cytokine storm resolved, and the patient was ultimately safely discharged from the hospital.
Identifiants
pubmed: 33072589
doi: 10.3389/fonc.2020.562625
pmc: PMC7531270
doi:
Types de publication
Case Reports
Langues
eng
Pagination
562625Informations de copyright
Copyright © 2020 Keiffer, French, Wilde, Filicko-O'Hara, Gergis and Binder.
Références
Nat Commun. 2020 Aug 6;11(1):3924
pubmed: 32764665
Int Immunopharmacol. 2008 Nov;8(11):1595-601
pubmed: 18664393
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Semin Immunol. 2014 Feb;26(1):88-96
pubmed: 24594001
J Pediatr Hematol Oncol. 2017 Apr;39(3):214-216
pubmed: 28060106
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Ann Oncol. 2020 Jul;31(7):961-964
pubmed: 32247642
Cancer Discov. 2016 Jun;6(6):664-79
pubmed: 27076371
Clin Exp Immunol. 2015 Jun;180(3):361-70
pubmed: 25683099
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Acta Haematol. 2007;118(3):153-9
pubmed: 17890847
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
Blood. 2008 Nov 15;112(10):3959-64
pubmed: 18784373
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Infect Dis. 2020 Apr 17;:
pubmed: 32301997
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Clin Drug Investig. 2020 Jun;40(6):511-518
pubmed: 32337664
J Med Virol. 2020 Apr 16;:
pubmed: 32297987
J Pediatr Hematol Oncol. 2017 Nov;39(8):614-617
pubmed: 29068868